Jason S. Starr, DO, discusses his approach to dose reduction of cabozantinib in patients with neuroendocrine tumors.
Jason S. Starr, DO
Jason S. Starr, DO, is an assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at Mayo Clinic.
Articles by Jason S. Starr, DO
Jason S. Starr, DO, discusses the significance of the extrapancreatic neuroendocrine tumor cohort of the phase 3 CABINET trial of cabozantinib.
Jason S. Starr, DO, discusses the CABINET trial of cabozantinib in pancreatic neuroendocrine tumors.
Latest Updated Articles
Improved Survival Observed in CABINET Trial of Pancreatic NETsPublished: September 17th 2025 | Updated: